Evidence map›Paper›PMID 38743139›Full record

Observational studyWiener klinische Wochenschrift2025

25 years of lipid-lowering therapy: secular trends in therapy of coronary patients.

Magdalena Ratz, Johannes B Vogel, Heike Kührer, Christoph H Säly, Axel Mündlein, Alexander Vonbank, Arthur Mader, Peter Fraunberger, Andreas Leiherer, Heinz Drexel

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Wiener klinische Wochenschrift, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Magdalena RatzPrivate University in the Principality of Liechtenstein (UFL), Triesen, Liechtenstein.ORCID http://orcid.org/0009-0007-8962-0749
Johannes B VogelPrivate University in the Principality of Liechtenstein (UFL), Triesen, Liechtenstein.ORCID http://orcid.org/0009-0009-5443-860X
Heike KührerVorarlberg Institute for Vascular Investigation & Treatment, (VIVIT), Carinagasse 47, 6800, Feldkirch, Austria.
Christoph H SälyPrivate University in the Principality of Liechtenstein (UFL), Triesen, Liechtenstein.
Axel MündleinVorarlberg Institute for Vascular Investigation & Treatment, (VIVIT), Carinagasse 47, 6800, Feldkirch, Austria.
Alexander VonbankPrivate University in the Principality of Liechtenstein (UFL), Triesen, Liechtenstein.
Arthur MaderVorarlberg Institute for Vascular Investigation & Treatment, (VIVIT), Carinagasse 47, 6800, Feldkirch, Austria.
Peter FraunbergerPrivate University in the Principality of Liechtenstein (UFL), Triesen, Liechtenstein.
Andreas LeihererPrivate University in the Principality of Liechtenstein (UFL), Triesen, Liechtenstein. andreas.leiherer@vivit.at.ORCID http://orcid.org/0000-0003-3776-5704
Heinz DrexelPrivate University in the Principality of Liechtenstein (UFL), Triesen, Liechtenstein. vivit@lkhf.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimGuidelines on dyslipidemia and lipid-lowering therapy (LLT) over the years recommend lower low-density lipoprotein cholesterol (LDL-C) goals by more intense therapy. Nevertheless, LDL‑C has increased in the general population. Real-world trends of LLT medication as well as of LDL‑C levels in cardiovascular high-risk patients are unclear.

methodsFrom 2158 patients who were referred for elective coronary angiography, lipid medication was analyzed at admission in three cardiovascular observational studies (OS) over the last 25 years: OS1: 1999-2000, OS2: 2005-2008 and OS3: 2022-2023. The three studies were performed at the same cardiology unit of a tertiary care hospital in Austria.

resultsThe proportion of patients without LLT significantly decreased from OS1 through OS2 to OS3 (49.4%, 45.6%, and 18.5%, respectively, p

conclusionWe conclude that during the observational period of a quarter of a century, treatment intensity increased and LDL‑C levels improved considerably. Guidelines apparently matter in this high-risk population and are considered by primary care physicians.

Indexed as

Coronary Artery DiseaseDyslipidemiasHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsPractice Patterns, Physicians'AgedAustriaCholesterol, LDLFemaleHumansMaleMiddle AgedTreatment OutcomeCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsCardiovascular diseaseCoronary angiographyESC/EAS guidelinesLDL cholesterolStatin

Identifiers

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.